Galera Therapeutics shareholders reject liquidation and dissolution plan

Galera Therapeutics, Inc.

Proposal to approve dissolution received 13,938,893 FOR and 18,075,579 AGAINST; not approved.
Proposal to adjourn for additional proxy solicitation also failed: 14,036,711 FOR vs 17,977,422 AGAINST.
Company has discontinued business activities and lacks resources; board to explore alternatives.
Special meeting held October 17, 2024; 32,061,280 shares (58.94% of outstanding) represented.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.